课题基金 / 基金详情

项目摘要

项目成果

HUGO W MOSER的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项第三阶段的双盲安慰剂对照试验,用于120名男性患者的洛伦佐斯油治疗 肾上腺脊髓神经病和120名有症状的女性携带者有类似的综合征。试验后的随访 每例疗程为3年。试验的主要目的是测试洛伦索斯油的疗效 延缓单纯肾上腺髓神经病(AMN)患者残疾进展的治疗。纯AMN和 有症状的女性携带者代表X-ALD的表型,特征是进行性非炎症性 脊髓长束的轴索病症。由于疾病进展的非炎症性, 直到最近,使用传统影像方法对脊髓病理进行视觉评价仍是一种 这是一个巨大的挑战。与资源合作允许磁化转移(MT)的发展 提供高空间分辨率和足够的SNR以区分灰质和白质对比度的成像 颈髓,允许在一个视野内看到脊髓的背柱在脊髓的C1至C5之间 1.5特斯拉。这使得首次对单纯AMN患者的脊髓束进行了活体评估。有很大的意义 单纯AMN男性、有症状的女性携带者和年龄匹配的对照组之间MT的定量差异。 定量检测背柱功能与背柱功能异常呈显著正相关 测量大脚趾振动敏感阈值。 根据我们与资源合作的初步结果,当前试验采用了量化修改 对颈髓的CT评估作为次要结果测量和监测进展的工具 快速评估治疗方法。X-ALD的神经学方面还没有明确的治疗方法。发展中的 灵敏的定量生物标志物对于快速评估新的治疗药物至关重要。当前的中流砥柱 疾病评估采用临床分级标准,如EDSS(扩展残疾状态量表)、改良RAKING 量表、成人肾上腺脑白质营养不良量表等。这些量表相对不那么敏感,需要大量样本和 长期随访,以获得足够的能力来检测进展中的显著差异。为了绕过 与传统的临床进展标志物相关的困难,非常重视发展 对轴突和髓鞘特异的超微结构异常敏感的神经成像替代物 并可在纵向上可靠地量化,与资源的协作对此至关重要。在……里面 与该资源合作,我们希望扩展我们的神经成像终端,以采用更好的敏感度 更高的场以及包括扩散张量成像(DTI)量化、柱的纤维跟踪和NAA Cho测量较大的脐带部分(由于光谱学的较低分辨率)。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase-III double blinded placebo controlled trial for Lorenzos oil treatment in 120 men with pure Adrenomyeloneuropathy and 120 symptomatic female carriers with a similar syndrome. The trial follow-up duration is for 3 years in each patient. The main aim of the trial is to test the efficacy of the Lorenzos Oil treatment in slowing disability progression in pure Adrenomyeloneuropathy (AMN) patients. Pure AMN and symptomatic female carriers represent the phenotypes of X-ALD, characterized by progressive non-inflammatory axonopathy in the long tracts of the spinal cord. Due to the non-inflammatory nature of the disease progression, visual appreciation of the spinal cord pathology using conventional imaging modalities was until recently a significant challenge. The collaboration with the resource allowed development of magnetization transfer (MT) imaging that provides high spatial resolution and sufficient SNR to distinguish gray and white matter contrast in the cervical spinal cord, allowing visualization of the dorsal column between C1 to C5 of the spinal cord at a field of 1.5 Tesla. This enabled first in vivo evaluation of the spinal cord tracts in pure AMN patients. There were significant quantitative MT differences between men with Pure AMN, symptomatic female carriers and age-matched controls. The abnormality in dorsal column correlated significantly with the dorsal column function tested by quantitatively measuring great toe vibration sensitivity threshold. Based on the initial results of our collaboration with the resource, the current trial employs quantitative modified MT evaluation of the cervical cord as a secondary outcome measure and as a tool for monitoring progression and rapidly evaluating therapy. There is no definitive treatment for neurological aspects of X-ALD. Development of sensitive quantitative biomarker is crucial for rapid evaluation of newer therapeutic agents. Current mainstay of disease evaluation is employing clinical rating scales such EDSS (Expanded Disability Status Scale), modified Rankin scale, Adult adrenoleukodystrophy scale etc. These are relatively less sensitive and require a large sample size and long follow-up to achieve adequate power for detecting significant differences in progression. To circumvent the difficulties associated with conventional clinical markers of progression, there is great emphasis on development of neuroimaging surrogates that are sensitive to ultrastructural abnormalities, specific to axonal and myelin pathology and can be reliably quantified longitudinally, for which the collaboration with the resource is essential. In collaboration with the resource, we hope to expand our neuroimaging endpoints to employ the better sensitivity of higher field as well as include diffusion tensor imaging (DTI) quantification, fiber tracking for the columns, and NAA and Cho measures for larger sections (due to the lower resolution of spectroscopy) of the cord.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PLACEBO-CONTROLLED STUDY OF X-ALD DIET THERAPY
  • 批准号:
    7604721
  • 项目类别:
  • 资助金额:
    $0.35万
  • 财政年份:
    2006
  • 负责人:
    HUGO W MOSER
  • 依托单位:
INTERNET MULTICENTER THERAPEUTIC TRIALS OF X LINKED ADRENOLEUKODYSTROPHY
THERAPEUTIC TRIALS OF X-LINKED ALD: PHASE III; LORENZO*
STUDIES IN ADRENOMYELONEUROPATHY
  • 批准号:
    7200729
  • 项目类别:
  • 资助金额:
    $1.17万
  • 财政年份:
    2005
  • 负责人:
    HUGO W MOSER
  • 依托单位:
海外基金